How falling sequencing costs are accelerating clinical adoption.

In this Amati Insights call, we discuss how advances in genomic sequencing are driving a new phase of adoption in healthcare, with important implications for diagnostics companies and investors.

The development of next generation sequencing (NGS) has caused a dramatic fall in the cost of reading the human genome, bringing it to a level where sequencing is no longer the limiting factor. Instead, attention has shifted to where genomic information delivers the greatest clinical and economic value.

One of the clearest areas of momentum is clinical diagnostics, particularly in oncology. New liquid biopsy techniques now allow clinicians to detect circulating tumour DNA from blood tests, enabling earlier diagnosis, improved monitoring after treatment, and more targeted therapies.

Beyond cancer, whole genome sequencing is increasingly viewed as best practice in paediatrics and rare disease, where early genetic diagnosis can materially improve outcomes and reduce long-term healthcare costs.

As adoption accelerates, a fast growing ecosystem of specialist genomics and diagnostics companies is emerging.

In the video we explore how the competitive dynamics are evolving, and potential opportunities for investors.